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ABSTRACT 
 
Objective  
 
To compare the effectiveness of polyglactin mesh, and polydioxanone or 
polyglactin sutures in women having pelvic organ prolapse surgery.   
 
Methods  
 
Randomised controlled trial with a factorial 2x2 design of polyglactin mesh or 
not, and polydioxanone or polyglactin suture.  Outcomes were assessed using 
questionnaires at baseline and on the third day and at 6 months after surgery. 
Women were also examined clinically at 3 months after surgery.  The primary 
outcome was the subjective improvement in prolapse symptoms and quality of 
life scores from baseline to 6 months.   
 
Results 
 
There was a subjective improvement in the prolapse symptom score from 
baseline to 6 months after surgery (mean difference of 9.2 (95% CI for 
difference 7.2 to 11.2, P<0.001) and an improvement in the mean quality of 
life score over the same period with a reduction of 3.4 (95% CI for difference 
2.4 to 4.3, P<0.001).  However there were no significant differences in the 
mean difference in prolapse system and quality of life score according to the 
randomised groups.  The majority (86%) of women were satisfied with their 
surgery.   
 
Conclusions 
 
Our study demonstrated at short term follow up there were no significant 
differences in the mean difference in prolapse system and quality of life 
scores after surgery using polyglactin mesh or not, polyglactin or polyglactin. 
sutures but the numbers were to small for a definitive conclusion.  Longer 
term follow up and a larger trial are required.   
 
(Keywords Pelvic organ prolapse, randomised control trial surgical mesh, 
polydioxanone, polyglactin ) 
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INTRODUCTION 
 
Surgery for pelvic organ prolapse (POP) is notoriously prone to failure: up to 
30% of women require a second or subsequent repair (1).  Surgical failure 
may be attributed to a number of factors.  Both patient factors (poor tissues, 
impaired healing processes and high intra-abdominal pressure due to obesity, 
constipation or chest conditions) and surgical factors (inappropriate choice of 
suture material or operation, or poor surgical technique) may contribute to 
poor outcomes (2, 3).   
 
In an attempt to improve surgical factors, reinforcement of the fascial defect 
and its repair has been advocated using mesh or graft placement.  After 
surgical correction of the hernial defect the mesh reinforces the repair by 
acting as scaffolding for new tissue regeneration, and support to attenuated 
areas, thus augmenting the natural function of the damaged tissue. (1, 3). 
Mesh placement is easy to perform and has been successful elsewhere, 
notably in hernia surgery.  However, controversy exists regarding the choice 
of mesh to use, especially in women having primary surgery.   
 
Recent literature has highlighted the danger of erosion with non-absorbable 
grafts, but there is little evidence to guide the choice between biological or 
synthetic absorbable material, nor indeed whether any use of mesh is 
effective in prolapse surgery.  
 
A recent update of the Cochrane Review of surgery for prolapse has identified 
six small RCTs which evaluated the use of mesh or not for women having 
anterior and/or posterior prolapse surgery.  Differences in inclusion criteria or 
interventions (eg types of women, operations or mesh/graft inlay) generally 
precluded useful meta-analysis or reliable conclusions.  However, there was 
some evidence from two of these (5, 6) that absorbable polyglactin mesh 
(Vicryl) might reduce objective (anatomical) prolapse recurrence compared 
with anterior repair alone, although the numbers were too few to evaluate 
morbidity or clinical outcomes.  Polyglactin is a synthetic absorbable mesh 
which is inert, porous, and flexible. It loses 50% of its original strength at 14 
days and so acts as initial scaffolding for new tissue regeneration after which 
it is completely absorbed. (5, 6) 
 
The choice of suture material is also controversial, in that no RCTs exist to 
guide the choice of the most effective one. (4)  Traditionally a polyglactin 
suture has been used for prolapse surgery.  It is a synthetic polyfilament 
suture, which loses 50% of its original strength at 14 days. More recently 
polydioxanone, a single-stranded, absorbable suture has been adopted by 
some surgeons.  This suture has similar tensile strength and knot security to 
polyglactin but has the advantage that it maintains 50% of its original strength 
for 21 days. (7)  This may be particularly advantageous in POP reconstructive 
surgery where abdominal pressure may affect the healing tissue 
postoperatively by acting as a stress factor.  Additionally, because it is a 
monofilament suture it may be associated with a lower risk of perioperative 
infection.   
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In view of these uncertainties, we carried out a randomised controlled trial to 
evaluate the use of absorbable polyglactin mesh and to compare the two 
sutures in women having POP surgery.  The aim of our study was to assess 
the difference in the mean prolapse symptom and quality of life scores in the 
study groups at 6 months after surgery.   
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PATIENTS AND METHODS 
 
Ethical approval was obtained form the Grampian Research Ethics 
Committee.  Women scheduled for POP surgery were identified from the 
waiting lists or admission diaries of the consultants participating in the trial. 
Women were provided with trial information on admission and invited to 
participate.   
 
Eligible women provided informed signed consent to the trial and long term 
follow up.  All women admitted with grade 2 or more POP who were willing to 
participate in the trial were eligible.  Women undergoing concurrent vaginal 
hysterectomy or continence procedures were also eligible.  They were 
counselled and consented for the trial by a research assistant or their 
consultant gynaecologist and then completed a baseline questionnaire.   
 
Women were randomised into receiving polyglactin mesh or not, and either a 
polydioxanone or a polyglactin suture for the repair of the pubocervical and/or 
the rectovaginal fascia using a 2x2 factorial design.  XX 
{Insert ref: FA McAlister, SE Straus, DL Sackett and DG Altman, Analysis and 
reporting of factorial trials: a systematic review, JAMA 289 (2003), pp. 2545–
2553.} 
Thus there were four groups, enabling separate analysis of mesh versus no 
mesh, and polydioxanone versus polyglactin sutures, as well as interactions 
between the two interventions.  Allocation to groups was carried out using a 
secure method of concealment of randomisation (remote computer allocation) 
on the afternoon before surgery.   
 
The group allocation was concealed from the women and the ward staff, 
although blinding in theatre was not possible, as theatre staff needed to 
prepare appropriate sutures and mesh for the surgeons before surgery.  The 
surgeon performing the operation completed a questionnaire in theatre giving 
details of the operation performed, complications and deviation from the 
allocated treatment.  
 
Women completed a postoperative questionnaire on the third day after their 
surgery.  They were clinically reviewed at 3 months after surgery for a 
subjective and objective assessment of their symptoms by one of the authors 
(who was blind to group allocation until after examination), and were given 
advice or further treatment if required.  Finally they completed a postal 
questionnaire six months after operation.   
 
Primary outcome assessment was by participant self-complete questionnaire, 
thus avoiding interviewer bias.  A researcher who was blind to the unit of 
randomisation conducted the data collection and analysis, using study 
numbers only to identify women and questionnaires.  All women were actively 
followed up with analysis based on the intention to treat principle.  All 
analyses were predefined to avoid bias.  A data base was designed for data 
entry.  
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The primary outcome was based on change in a pelvic symptom score 
derived from the seven most common prolapse symptoms.  (XX ref) 
{insert ref to study: C. Bugge, S. Hagen, and C. M. A. Glazener. The POPPY 
study: a qualitative evaluation of a pelvic organ prolapse outcome 
questionnaire (Abstract). ICS UK, Annual General Meeting, Glasgow, UK, 
March, 2005.} 
The minimum score was 0 (all symptoms rated as ‘never’) and the maximum 
was 21 (all symptoms rated as ‘all of the time’).  The score was calculated at 
baseline (before surgery) and again at 6 months after surgery.  A symptom 
score change was calculated for each woman for the difference between 
these two scores.  Quality of life attributed to prolapse symptoms was 
calculated by asking, “Overall, how much do your prolapse symptoms 
interfere with your everyday life?” The minimum score was 0 (‘not at all’) and 
the maximum was 10 (‘a great deal’).   
 
Data verification was carried out by having data entry limits in place, by 
querying outlying or suspect variables, and by spot checking data from 17 
participants.  A 2.9% data error rate was found and variables corrected if 
necessary.  Data analysis was carried out using independent t-tests and Chi - 
squared tests as appropriate.   
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RESULTS 
 
In total, 83 women were considered for randomisation (Figure 1).  Of these, 5 
refused and 5 were not eligible.  Of the five women who refused to participate 
in the trial, four refused because they did not wish to or could not attend for 
follow up and one woman was worried about the use of a foreign material 
such as mesh.  Of the 73 randomised women, a further 7 were found to be 
ineligible after randomisation (Figure 1), resulting in 66 properly randomised 
of 71 potentially eligible women (93%).   
 
Thus, 66 women were randomised (Figure 1): 32 were allocated to mesh and 
34 to no mesh; 33 were allocated to polydioxanone and 33 to polyglactin.  The 
groups were comparable on baseline characteristics (Table 1).  Six women in 
the mesh/no mesh comparison did not receive the allocated treatment (see 
Figure 1).  For the five women who did not receive mesh as allocated, the 
reasons included: lack of theatre time for the insertion of mesh; poor access 
to tissue; a concern that using mesh in addition to TVT would increase the 
infection risk.  Only one woman in the no mesh arm actually received mesh as 
the gynaecologist deemed that the use of mesh was clinically indicated  
because the tissues were deficient and friable.   
 
Two (3%) women experienced short term adverse effects: one returned to 
theatre for postoperative bleeding and one women required suprapubic 
catheterisation for urinary retention.   
 
In total, 58/66 (88%) women were reviewed by a gynaecologist 3 months after 
operation and 62/66 (94%) women completed the 6 month follow up 
questionnaire (Figure 1).  At the 3 months examination, 10/58 (17%) of 
women reported a residual subjective feeling of something coming down, 
although this was unrelated to their randomised groups.  Ten women said that 
their symptoms were unchanged (8) or worse (2) but only six women (10%) 
had a residual stage 2 anterior wall prolapse on objective examination.  One 
woman had had a pessary fitted by her GP, and a further 7 were referred for 
formal physiotherapy or other conservative management.   
 
At baseline, the mean prolapse symptom score was 13.5 (range 3 to 28), 
indicating that all of the women had at least one symptom.  At 6 months after 
surgery, the mean prolapse symptom score was 4.3 (range 0 to 22).  There 
was a significant improvement overall at 6 months, mean difference 9.2 (95% 
CI for difference 7.2 to 11.2, P<0.001, paired t-test).  However, there were no 
significant differences by randomised groups in the change in symptom score 
over 6 months (Table 2).   
 
Similarly, the quality of life score at baseline was 4.8 (range 0 to 10), with no 
differences between the trial groups.  The mean quality of life score at 6 
months after surgery was 1.6 (range 0 to 10) this improved significantly after 
prolapse surgery, with a mean difference of 3.4 (95% CI for difference 2.4 to 
4.3, P<0.001, paired t-test).  However, there were no differences between the 
groups in change in quality of life at 6 months (Table 2).   
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Regarding satisfaction, 49/59 (83%) women were very or fairly satisfied with 
their surgery 6 months later.  However, there were no significant differences 
according to trial groups.   
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DISCUSSION 
 
The results of this prospective randomised control trial showed that 
recruitment for POP surgery trials was very successful with 66 women (93%) 
out of the 71 eligible women agreeing to participate in the trial. 
 
Our trial showed that there was a subjective improvement in mean prolapse 
symptom score from baseline to 6 months after surgery, with a mean 
decrease in score of 9.2 and an improvement in the mean quality of life score 
from the baseline to 6 month follow up with a mean decrease of 3.4 units. The 
majority (83%) of women were satisfied with their surgery and said that their 
prolapse did not bother them any more, and only a minority had residual 
prolapse of Stage 2 (10%).   
 
However there were no significant differences in the mean difference in 
prolapse system score and quality of life score between the trial groups after 
surgery at short term follow up (Table 2).  This differs from the results of a trial 
evaluating the use of polyglactin mesh evaluating the use absorbable mesh 
for anterior vaginal wall repair performed by Sand et al. (5) who analysed 143 
women comparing anterior endopelvic fascial plication with and without the 
utilisation of Polyglactin mesh at 24 month follow up.  The authors reported 
significantly higher objective success rates with the use of the mesh (75% 
verus 57%; P = 0.02) but did not report subjective prolapse symptoms or 
effect on quality of life. (5)  Weber et al. (9) also compared classical anterior 
repair with and without the use of polyglactin mesh.  Although at a mean 
follow-up of 24 months they found that the addition of polyglactin mesh did not 
improve the objective cure rate compared with standard anterior 
colporrhaphy, the groups were small.  No data on subjective outcomes were 
provided.   
 
The explanation for the difference in the findings of these three studies (Sand, 
Weber and the current study) may be explained in part by differences in 
sample sizes, in methods of assessing outcomes and types of outcomes, and 
length of follow-up.  In addition, we analysed the data from women having 
anterior and posterior repairs together.   
 
Complications related to mesh prosthesis include, infection, sinus tract 
formation, seroma, erosion and fistula formation. (10-12)  Our study showed 
that surgery with the use of Polyglactin mesh was associated with very few 
perioperative and early post operative complications with no mesh erosions 
noted to date. This was comparable to the findings in the trials performed by 
Sand et al (5) and Weber (9), who reported no mesh-related complications in 
their study.   
 
Our trial was too small to demonstrate differences attributable to the two 
sutures and no other trials have been identified that address this issue (ref 
Cochrane review 4).  Nevertheless, the theoretical differences between the 
sutures in terms of tensile strength, half life, potential for infection and 
handling ease would suggest that further evaluation by RCT would be 
warranted.   
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The satisfaction rate recorded at 6 month follow up showed that the majority 
of women were fairly or very satisfied with the results of their surgery (83%) 
but the numbers were too few to differentiate between the randomised 
groups.  Four (13%) women were very dissatisfied with their surgery: two of 
them had recurrent prolapse.   
 
The strengths of our study were that it was a prospective randomised control 
trial in which the principal outcome assessors were blinded to the 
randomisation and the patients were blinded to the treatment that they 
received thus reducing bias.  The recruitment to the trial was excellent (93%) 
with 88% being reviewed at 3 months and 94% women responding to the 6 
month questionnaire.  The study groups were comparable at baseline on 
mean prolapse symptom score, quality of life score and other clinical and 
sociodemographic factors.   
 
The weakness of our study was that participant numbers were too small to 
demonstrate statistical significance between the randomised groups.  
Furthermore, the follow up period of 6 months was too short to demonstrate 
clinical effectiveness, but long term follow up is planned.   
 
We would also suggest that an objective assessment of the POP by a 
validated and standardised system such as the POPQ scoring system should 
be used before and after surgery to enhance generalisability.  The 
randomisation of trial participants should be done on the day of surgery or as 
late as possible to reduce the numbers of women who are not fit or unsuitable 
for surgery being randomised.  Larger numbers of participants and longer 
term follow up will help to more accurately assess the impact of the use of 
polyglactin mesh, polydioxanone and polyglactin sutures.   
 
Future research is particularly warranted to compare the use of non 
absorbable or partially absorbable mesh with no mesh to assess the impact 
on POP surgery, as this is becoming increasingly common in clinical practice 
without an adequate evidence base.   
 
 
CONCLUSIONS 
 
Our trial established that running an RCT of different methods of prolapse 
surgery in a busy tertiary referral unit involving seven gynaecologists could be 
carried out with minimal disruption to routine services.  The recruitment, 
randomisation and retention of the women was excellent.  Although our trial 
did not demonstrate any significant difference in prolapse symptoms and 
quality of life after surgery at short term follow up, the numbers were to small 
to give reliable results.  A larger trial is warranted.   
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Table 1 Baseline characteristics by randomised allocation 
 Mesh (32) No mesh 
(34) 
Polydioxanone 
(33) 
Polyglactin 
(33) 
Age >= 60 years 18/32 20/34 19/33 19/33 
Parity 
Para 1 or less 
Para 2 or more 
 
 
15/32 
17/32 
 
17/34 
16/34 
 
 
14/33 
19/33 
 
18/33 
14/33 
Menopause 28/32 28/34 28/33 28/33 
Smoking 1/32 3/34 3/33 1/33 
HRT  5/32 2/34 2/33 5/33 
COPD 7/32 7/34 7/33 7/33 
PFMT 9/32 9/34 8/33 10/33 
Primary operation 
Secondary 
operation 
27/32 
5/32 
30/34 
4/34 
28/33 
5/33 
29/33 
4/33 
Preoperative ring 
use 
8/32 4/33 4/33 8/32 
Type of prolapse 
 Cystocele 
 Rectocele 
 Both (19) 
 Paravaginal  
 
16/32 
7/32 
8/32 
2/32 
 
12/34 
6/34 
11/34 
0/34 
 
16/33 
5/33 
9/33 
1/33 
 
12/33 
8/33 
10/33 
1/33 
Concomitant 
operations 
 Hysterectomy  
Cervical amputation 
 TVT 
 Other  
 
 
6/32 
8/32 
7/32 
0/32 
 
 
8/34 
10/34 
6/34 
2/34 
 
 
9/33 
8/33 
5/33 
0/33 
 
 
5/33 
10/33 
8/33 
2/33 
 
COPD chronic obstructive airway disease 
HRT hormone replacement therapy 
Polydioxanone  
PFMT pelvic floor muscle training 
TVT tension free vaginal tape 
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Table 2 Change in prolapse symptom and quality of life score between 
baseline and at 6 months after prolapse surgery 
 
 Mean change 
in Symptom 
Score 
at 6 months 
N, mean (SD) 
Mean 
difference 
[95% CI for 
difference] 
Mean change 
in QoL from 
baseline to 6 
months 
N, mean (SD) 
Mean 
difference 
[95% CI for 
difference] 
Mesh 29, -9.6 (8.6) 26, -3.8 (3.5) 
No mesh  32, -8.8 (7.3) -0.8 
[-4.9 to +3.3] 
32, -3.0 (3.8) -0.8 
[-2.8 to +1.1] 
     
Polydioxanone  29, -9.1 (9.0) 26, -3.1 (3.5) 
Polyglactin  32, -9.3 (6.9) 0.2 
[-3.8 to +4.3] 
32, -3.6 (3.8) 0.5 
[-1.5 to +2.4] 
     
 
 
CI confidence interval 
N number 
Polydioxanone  
QoL quality of life  
SD standard deviation 
 
 13 
Impress Flow diagram (figure 1) 
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Women admitted for 
prolapse surgery 
N=83 
 
Women 
randomised 
N=73 
Not randomised 
5 refused  
3 unfit for operation 
2 unable to give consent 
Women in 
trial 
N=66 
Women not having 
prolapse surgery 
4 unfit for operation 
1 operation deferred 
2 did not have prolapse 
Mesh N=32 No mesh N=34 PDS N=33 Vicryl N=33 
Treatment allocated  
Treatment received  
Mesh N=27 * 
No mesh N=33** 
 
Vicryl N=33 PDS N=33 
* Mesh not used due to poor access (2); not enough theatre time (2); TVT caused worries re increased infection 
risk (1) 
** Mesh used as tissue were deficient and friable 
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58 /66 women came for 3 month follow 
up 
32/34 women from 
the no mesh group 
27/33 of women in the, 
mesh group  
62/66 women returned their 6 month 
questionnaire   
29/33 women 
from pds group 
26/32 of women in the, 
mesh group  
31/33 of women in the, 
mesh group  
33/34 women 
in the no mesh 
group 
29/32 women 
from the mesh 
group 
33/33 of 
women in the 
Vicryl group 
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